Clinical Trials List
2020-08-01 - 2028-06-30
Phase II
Recruiting6
ICD-10Z12.6
Encounter for screening for malignant neoplasm of bladder
ICD-9V76.3
Special screening for malignant neoplasms, bladder
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/06/01
Investigators and Locations
Co-Principal Investigator
- Chung-Pin Li Digestive System Department
- Yi-Ping Hung Division of Hematology & Oncology
- Pei-Chang Lee Digestive System Department
- Ming-Huang Chen Division of Hematology & Oncology
- San-Chi Chen Division of Hematology & Oncology
- Yi-Jen Chen Division of Obstetrics & Gynecology
- Yee Chao 未分科
- Rheun-Chuan Lee 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HUAI-CHENG HUANG Division of Hematology & Oncology
- SHIH-HUNG YANG 未分科
- Hsin-Yu Liu Division of Ophthalmology
- Chih-Hung Hsu 未分科
- Wen-Fang Cheng 未分科
- SHIH-HUNG YANG Division of Hematology & Oncology
- Kun-Huei Yeh 未分科
- 廖斌志 Division of Hematology & Oncology
- 郭弘揚 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hung-Chih Hsu 未分科
- Po-Jung Su 未分科
- Cheng-Tao Lin Division of Obstetrics & Gynecology
- Yun-Hsin Tang Division of Obstetrics & Gynecology
- 周宏學 Division of Obstetrics & Gynecology
- Wen-Chi Chou 未分科
- Yung-Chia Kao 未分科
- Gigin Lin Division of Radiology
- Min-Yu Chen Division of Obstetrics & Gynecology
- Chyong-Huey Lai Division of Obstetrics & Gynecology
- Wen-Chi Shen 未分科
- Ming-Mo Hou 未分科
- 周宏學 未分科
- 陳威君 Division of Obstetrics & Gynecology
- Angel Chao Division of Obstetrics & Gynecology
- Tsai-Sheng Yang 未分科
- Chia-Hsun Hsieh 未分科
- 吳教恩 未分科
- Ting-Chang Chang Division of Obstetrics & Gynecology
- 黃寬仁 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
480 participants